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Abstract
Background: Preceding intervertebral disc (IVD) degeneration, the cell phenotype in the nucleus pulposus (NP)
shifts from notochordal cells (NCs) to chondrocyte-like cells (CLCs). Microarray analysis showed a correlation
between caveolin-1 expression and the phenotypic transition of NCs to CLCs. With a clinical directive in mind, the
aim of this study was to determine the role of caveolin-1 in IVD degeneration. As a scaffolding protein, caveolin-1
influences several signaling pathways, and transforming growth factor (TGF)-β receptors have been demonstrated
to colocalize with caveolin-1. Therefore, the hypothesis of this study was that caveolin-1 facilitates repair by
enhancing TGF-β signaling in the IVD.
Methods: Protein expression (caveolin-1, apoptosis, progenitor cell markers, extracellular matrix, and
phosphorylated Smad2 [pSmad2]) was determined in IVDs of wild-type (WT) and caveolin-1-null mice and canine
IVDs of different degeneration grades (immunofluorescence, immunohistochemistry, and TUNEL assay). Canine/
human CLC microaggregates were treated with chondrogenic medium alone or in combination with caveolin-1
scaffolding domain (CSD) peptide and/or caveolin-1 silencing RNA. After 28 days, gene and protein expression
profiles were determined.
Results: The NP of WT mice was rich in viable NCs, whereas the NP of caveolin-1-null mice contained more
collagen-rich extracellular matrix and fewer cells, together with increased progenitor cell marker expression,
pSmad2 TGF-β signaling, and high apoptotic activity. During canine IVD degeneration, caveolin-1 expression and
apoptotic activity increased. In vitro caveolin-1 silencing decreased the CLC microaggregate glycosaminoglycan
(GAG) content, which could be rescued by CSD treatment. Furthermore, CSD increased TGF-β/pSmad2 signaling at
gene and protein expression levels and enhanced the anabolic effects of TGF-β1, reflected in increased extracellular
matrix deposition by the CLCs.
Conclusions: Caveolin-1 plays a role in preservation of the NC phenotype. Additionally, it may be related to CLC
apoptosis, given its increased expression in degenerated IVDs. Nevertheless, CSD enhanced CLC GAG deposition in
vitro, and hence the increased caveolin-1 expression during IVD degeneration may also facilitate an ultimate
attempt at repair. Further studies are needed to investigate how caveolin-1 modifies other signaling pathways and
facilitates IVD repair.
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Background
Low back pain has been identified as one of the highest
burden conditions by the World Health Organization
and is the most common type of pain restricting daily
activity [1]. Low back pain is strongly related to interver-
tebral disc (IVD) degeneration [2]. The IVD consists of a
central nucleus pulposus (NP) and outer annulus fibro-
sus. During IVD degeneration, the glycosaminoglycan
(GAG) and water content of the NP decreases. Like
humans, dogs experience spontaneous IVD degeneration
with similar characteristics [3]. In both species, noto-
chordal cells (NCs) are replaced by chondrocyte-like
cells (CLCs) in the NP during maturation and early IVD
degeneration. Therefore, the dog is considered to be a
suitable animal model for human IVD degeneration [3].
Dogs can be divided into chondrodystrophic (CD) and
nonchondrodystrophic (NCD) breeds on the basis of
their physical appearance. In CD dogs, replacement of
NCs by CLCs starts around 1 year of age and IVD dis-
ease typically develops around 3–7 years of age, whereas
in NCD dogs, NCs remain the predominant cell type
until middle or old age and if IVD disease develops it oc-
curs around 6–8 years of age [4]. Current treatments for
IVD disease (physiotherapy, medication, and surgery)
are focused on reducing pain and spinal cord and/or
nerve decompression but do not induce IVD repair.
Therefore, there is substantial interest in agents stimu-
lating biological repair of the degenerated IVD, resulting
in functional restoration [5]. Caveolin-1 could be such
an agent, as its advantageous effects have been demon-
strated in several tissue types [6–9].
The mammalian caveolin family consists of three pro-
teins (caveolin-1, -2, and -3), which are integral mem-
brane proteins essential for the structural integrity and
function of caveolae (flask-shaped invaginations of the
plasma membrane) of many differentiated cell types
[10–12]. Caveolin-1 is involved in endocytosis, the for-
mation and transport of caveolae, and cell adhesion and
migration [13]. Moreover, caveolin-1 is implicated in cell
cycle regulation, senescence (cell cycle arrest due to re-
sistance to external stimuli [10]), and apoptosis [14]. As
a scaffolding protein, it regulates signal transduction
[12], and caveolin-binding motifs have been identified in
several target proteins [7]. The effect of caveolin-1 on
signaling pathways is usually inhibitory due to sequestra-
tion and inactivation of molecules in caveolar mem-
branes, but signaling can also be enhanced by bringing
molecules together [7]. Altogether, caveolin-1 has been
shown to exert context-dependent effects (i.e., differing
per tissue/cell type, age, and stage of degeneration) [11].
Caveolin-1 is differentially expressed in the IVD. The
NP of early degenerated canine IVDs expresses lower
caveolin-1 levels than healthy canine NC-rich NPs [15].
In addition, the NP of wild-type (WT) mice is rich in
viable NCs, whereas the NP of caveolin-1-null mice con-
tains mainly CLCs [15]. In humans, CLCs derived from
degenerated IVDs express higher caveolin-1 levels than
CLCs from nondegenerated IVDs [16]. During IVD
degeneration, accelerated cell senescence takes place
[16, 17], and a positive relationship between caveolin-1
expression and premature stress-induced senescence
has been reported in articular cartilage [18] and the IVD
[16]. Altogether, this implies that caveolin-1 could play
an important role in IVD degeneration.
The aim of this study was to determine the role of
caveolin-1 in IVD degeneration. Transforming growth
factor (TGF)-β signaling is known to play a role in the
degenerative and regenerative processes of cartilaginous
tissues [19], and TGF-β receptors have been demon-
strated to colocalize with caveolin-1 [20]. Therefore, we
hypothesized that caveolin-1 modifies canonical TGF-β
signaling in the IVD and thereby facilitates repair. To as-
sess the effect of in vivo caveolin-1 depletion, we studied
murine caveolin-1-null IVDs. With a clinical directive in
mind, functional studies were focused on the effect of
caveolin-1 on CLCs because degenerated canine and hu-
man IVDs contain almost 100 % CLCs. Caveolin-1 ex-
pression and apoptosis levels were determined in canine
IVDs of different degeneration grades, and human and
canine CLCs were silenced for caveolin-1 and/or supple-
mented with caveolin-1 scaffolding domain (CSD) pep-
tide in vitro to determine the (regenerative) effect of
caveolin-1 on CLCs. In the present study, we show that
while caveolin-1 preserved the NC phenotype, its ex-
pression increased in degenerated IVDs. Given that CSD
supplementation enhanced the anabolic effects of TGF-
β1 on CLCs in terms of increased GAG deposition in
vitro, the increased caveolin-1 expression during IVD
degeneration may facilitate an ultimate attempt at repair
by decreasing the loss of GAGs.
Methods
Caveolin-1-null mice
Thoracic and lumbar spines were collected from 1.5-, 3-,
and 6-month-old caveolin-1-null (Cavtm1Mls, JAX®; The
Jackson Laboratory, Bar Harbor, ME, USA) and WT
mice (B6129SF2, JAX®) of the same genetic background.
Experimental procedures were performed according to
the guidelines of the Utrecht University Ethics Committee
(DEC 2008.III.01.001).
Paraffin-embedded tissue histology
Murine lumbar spines were fixed in 4 % neutral buffered
formaldehyde (Klinipath, Duiven, the Netherlands), dec-
alcified (7 days in 10 % ethylenediaminetetraacetic acid),
and embedded in paraffin. Midsagittal 5-μm sections
were mounted on KP+ microscope slides (KP-3056;
Klinipath), stained with hematoxylin and eosin and Alcian
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Blue/picrosirius red [21], and immunohistochemically
stained for Ki-67 and collagen type II (Table 1). An
ApopTag® Plus Peroxidase In Situ Apoptosis Detection
Kit (terminal deoxynucleotidyl transferase deoxyuri-
dine triphosphtate nick-end labeling [TUNEL] assay,
S7101; EMD Millipore, Billerica, MA, USA) was used
to detect apoptotic cells on lumbar midsagittal sec-
tions. All lumbar IVDs were evaluated (approximately
four IVDs per lumbar spine). Raw images of the sec-
tions were made using a Leica DFC420C digital camera
(Leica Microsystems, Buffalo Grove, IL, USA) mounted
to a BX60 microscope (Olympus America, Center Val-
ley, PA, USA) with the Leica Application Suite (V4.2)
software package. Adobe Photoshop CS6 software
(Adobe, San Jose, CA, USA) was used to manually
count (positively stained) cell numbers in each NP.
The percentage of nuclei that stained positive for
TUNEL over the total number of nuclei present was
determined for every murine NP in conjunction with
morphology to avoid false-positive results.
Immunofluorescent staining
Thoracic IVDs were snap-frozen and stored at −70 °C
until analysis. Ten-micrometer transverse cryosections
were stained for caveolin-1, phosphorylated Smad2
(pSmad2 indicating activated TGF-β signaling), and the
nucleus pulposus progenitor cell (NPPC) markers
tyrosine-like receptor Tie2 and disialoganglioside 2
(GD2) (Table 2). Within 48 h, confocal images were ob-
tained with a Zeiss LSM upright confocal laser scanning
microscope, and the sections were analyzed with Zen
software 2011 (Zeiss Microscopy, Thornwood, NY, USA)
in two or three transverse thoracic NP sections per ani-
mal. On the basis of the observed expression pattern,
caveolin-1, Tie2, and GD2 were scored as being present
or not present. The percentage of nuclei that stained
positive for pSmad2 over the total number of nuclei
present (pSmad2 ratio) was manually counted and calcu-
lated per murine NP, and the mean pSmad2 ratio was
determined per age group.
Caveolin-1 expression in canine IVD degeneration
Thirty-seven thoracolumbar or lumbosacral IVD sam-
ples from sixteen canine cadavers were studied. The
dogs were of different breeds (5 CD, 11 NCD), ages (1–
16 years), and sex (11 female, 5 male). The samples were
divided into five different grades of degeneration on the
basis of gross morphology of midsagittal sections, ran-
ging from Thompson grade I for healthy to Thompson
grade V for end-stage degeneration [22, 23]. The IVD
donors were chosen on the basis of equal representation
of all IVD degeneration grades (n = 8, 7, 8, 7, and 7 for
grades I–V, respectively). All dogs had been killed in un-
related research projects or were client-owned dogs that
were submitted to the Department of Pathobiology
Faculty of Veterinary Medicine, Utrecht University, for
necropsy. Five-micrometer-thick midsagittal consecutive
IVD sections were mounted on KP+ microscope slides
and processed for caveolin-1 immunohistochemistry
(Table 1) and a TUNEL assay. Thereafter, raw images of
the sections were made using a Leica DFC420C digital
camera mounted to a BX60 microscope and the Leica
Application Suite (V4.2) software package. Adobe Photo-
shop CS6 was used to manually count (positively
stained) TUNEL cell numbers, and the integrated option
“color range” was used to determine the area within the
NP that stained positive for caveolin-1 (caveolin-1 ratio)
in four randomly selected NP areas per IVD section.









Caveolin-1 Clone 2297, 610406
(BD Biosciences, San
Jose, CA, USA)
Mouse Citrate (10 mM),
70 °C, 60 minutes
0.3 % H2O2 + 10 %
goat serum
5 μg/ml in PBS Goat anti-mouse,
(K4001; Dako, Carpinteria,
CA, USA)
Ki-67 Clone SP6, RM-9106-S
(Thermo Scientific™,
Waltham, MA, USA)
Rabbit Citrate (10 mM),
80 °C, 90 minutes
0.3 % H2O2 + 10 %
goat serum






Iowa City, IA, USA)
Mouse 1 mg/ml pronase +
10 mg/ml
hyaluronidase,
37 °C, 30 minutes












Mouse 1 mg/ml pronase +
10 mg/ml hyaluronidase,
37 °C, 30 minutes
0.3 % H2O2 + 5 %
BSA/PBS
0.1 μg/ml (human)
or 0.07 μg/ml (canine)
in 5 % BSA/PBS
Goat anti-mouse,
(K4001; Dako)
Ab antibody, BSA bovine serum albumin, PBS phosphate-buffered saline
Midsagittal intervertebral disc sections were deparaffinized with xylene and graded ethanol. The primary antibody was applied at 4 °C overnight. In control
experiments, the primary antibody was replaced with mouse immunoglobulin G1 (3877; Santa Cruz Biotechnology), and no false-positive staining was observed.
The secondary antibody was applied for 60 minutes, and the sections were incubated with a liquid 3,3′-diaminobenzidinesubstrate chromogen system (K3468;
Dako) for 10 minutes. The slides were stained with Vector Hematoxylin QS solution (H3404; Vector Laboratories, Burlingame, CA, USA) for 10 seconds, dehydrated,
and mounted (H5000; Vector Laboratories)
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The mean percentage of nuclei that stained positive for
TUNEL over the total number of nuclei present in the
four randomly selected NP areas was determined in con-
junction with morphology to avoid false-positive results.
In vitro effects of caveolin-1 peptide on human and
canine CLCs derived from degenerated IVDs
CLC collection
In total, IVD tissue from 16 canine (11 CD, 5 NCD) and
3 human donors was collected. Complete spines (2–11
years of age, Thompson grade II or III) were collected
from dogs that had been killed in unrelated research
studies (approved by the Utrecht University Animal
Ethics Committee). IVD tissue of three human donors
(one male, two females, 47–63 years of age, Thompson
grade III) derived from the L2–L5 spinal region were ob-
tained at autopsy. Anonymous use of redundant tissue
for research purposes is a standard treatment agreement
with patients in University Medical Centre Utrecht (local
medical Ethics committee number 12-364). Thus, all
necessary consent from patients involved in the study
was present. The material was collected as part of the
activities of the tissue bank of the Department of
Pathology, UMCU Biobank, UMC Utrecht. The scien-
tific committee of the Department of Pathology at
UMC Utrecht (Wetenschappelijke Adviesraad Bio-
bank) approved the study. All tissue was used in line
with the code “Proper Secondary Use of Human Tissue”
as installed by the Dutch Federation of Biomedical Scien-
tific Societies [24].
Cell culture and experimental design
CLCs were collected from the canine and human NPs as
described previously [25] and thereafter expanded in
expansion medium [26]. NCD canine donors that
contained only CLCs in the NP were selected using
cytospins (Additional file 1). After the CLCs reached
80 % confluence in P2, they were plated in a 96-well
plate (CLS7007, Costar®; Corning, Corning Life Sciences,
NY, USA) at a density of 35,000 cells/well in 50 μl of
chondrogenic culture medium composed of high-glucose
Dulbecco’s modified Eagle’s medium+GlutaMAX (31966;
Invitrogen, Carlsbad, CA, USA) with 1 % P/S (P11-010;
GE Healthcare Life Sciences, Little Chalfont, UK), 1 %
ITS+ premix (354352; Corning Life Sciences), 0.04 mg/
ml L-proline (P5607; Sigma-Aldrich, St. Louis, MO,
USA), 0.1 mM ascorbic acid 2-phosphate (A8960;
Sigma-Aldrich), 1.25 mg/ml human serum albumin
(human CLCs; Sanquin, Amsterdam, the Netherlands)
or bovine serum albumin (canine CLCs, A9418; Sigma-
Aldrich), and 10 ng/ml TGF-β1 (240-B; R&D Systems,
Minneapolis, MN, USA). The microaggregates were
cultured for 14 days (21 % O2, 5 % CO2, 37 °C).
Caveolin-1 expression was silenced in CLCs from six
CD canine donors, and the following conditions were
tested: mock (100 nM Stealth™ RNAi Negative Control
Duplex; Invitrogen), silencing RNA (siRNA) (100 nM
caveolin-1 Stealth™ RNAi siRNA Duplex; Invitrogen),
and siRNA + CSD (100 nM caveolin-1 siRNA oligo and
10 μM CSD, ALX-153-064; Enzo Life Sciences, Farm-
ingdale, NY, USA). The canine CLCs were transfected
with 3 μl/ml Lipofectamine™ RNAiMAX (13778-075;
Invitrogen) at the moment of plating. Six hours after
plating, the 96-well plates were centrifuged at 50 g for
5 minutes to induce microaggregate formation. Stealth™
RNAi siRNA Duplex (10620312; Invitrogen) was used
to silence caveolin-1 (NM_001003296): 5′ CACACC
AAGGAAAUCGACCUGGUCA 3′ (guanine-cytosine
[GC] percentage 52 %). Stealth™ RNAi Negative Control
Duplex (GC percentage 48 %, 12935-300; Invitrogen)
Table 2 Details of the immunofluorescence protocol
Antibody Specifications Host Dilution Secondary antibody
Tie2 324 (Santa Cruz Biotechnology) Rabbit 4 μg/ml Alexa Fluor® 594 AffiniPure Donkey Anti-Rabbit IgG
(711-165-152; Jackson ImmunoResearch, West Grove, PA, USA)
GD2 554272 (BD Biosciences) Mouse 10 μg/ml Alexa Fluor™ 488 Donkey Anti-Mouse IgG
(A21202; Molecular Probes/Invitrogen, Eugene, OR, USA)
Caveolin-1 2910 (Abcam) Rabbit 5 μg/ml Alexa Fluor® 594 AffiniPure Donkey Anti-Rabbit IgG
(711-165-152; Jackson ImmunoResearch)
pSMAD2 3101 s (Cell Signaling Technology,
Danvers, MA, USA)
Rabbit 5 μg/ml Alexa Fluor™ 488 Donkey Anti-Rabbit IgG
(A21206; Molecular Probes/Invitrogen)
Negative control Primary antibody omitted – – Alexa Fluor™ 488 Donkey Anti-Mouse IgG
(A21202; Molecular Probes/Invitrogen) + Alexa Fluor® 594 AffiniPure
Donkey Anti-Rabbit IgG (711-165-152; Jackson ImmunoResearch)
GD2 disialoganglioside 2, IgG immunoglobulin G, pSmad2 phosphorylated Smad2
The thoracic intervertebral discs were embedded in O.C.T. compound (14020108926; Leica Microsystems), transverse 10-μm cryosections were mounted on Superfrost
Plus slides (4951PLUS4; Thermo Scientific), and the sections were treated with phosphate-buffered saline (PBS) diluted 1:1 in Gibco TrypLE™ Express Enzyme (12605; Life
Technologies, Carlsbad, CA, USA) for 10 minutes at 37 °C. The sections were blocked with 3 % bovine serum albumin (BSA) and 0.25 % Triton X-100 (T8787;
Sigma-Aldrich, St. Louis, MO, USA) for 30 minutes and incubated overnight at 4 °C with the primary antibodies diluted in 1 % BSA in PBS. The secondary
antibody was diluted 1:250 in 1 % BSA and 0.1 % Triton X-100 in PBS and applied for 45 minutes at room temperature. The sections were mounted with
VECTASHIELD mounting medium with 4′,6-diamidino-2-phenylindole (H-1200; Vector Laboratories)
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was used to determine the effect of Stealth™ RNAi
siRNA Duplex versus background (mock).
To determine the optimal conditions for CSD to exert
its effects, CLCs from three human donors as well as
five CD and five NCD canine donors with the following
conditions were studied: T2 (chondrogenic culture
medium with 2 ng/ml TGF-β1), T2C10 (2 ng/ml TGF-β1
and 10 μM CSD), T2C25 (2 ng/ml TGF-β1 and 25 μM
CSD), T10 (10 ng/ml TGF-β1), T10C10 (10 ng/ml TGF-β1
and 10 μM CSD), and T10C25 (10 ng/ml TGF-β1 and
25 μM CSD).
Readout parameters
Two microaggregates per donor and condition were
snap-frozen at day 4, and RNA was extracted, cDNA
was made, and real-time quantitative polymerase chain
reaction was performed for the target genes aggrecan
(ACAN), a disintegrin and metalloproteinase with throm-
bospondin motifs 5 (ADAMTS5), activin receptor-like kin-
ase 1 (ALK1), activin receptor-like kinase 5 (ALK5), BCL2-
associated protein (BAX), B-cell CLL/lymphoma 2
(BCL2), caspase 3 (CASP3), caveolin-1 (CAV1), cyclin D1
(CCND1), collagen type I, alpha 1 (COL1A1), collagen
type II, alpha 1 (COL2A1), inhibitor of DNA binding 1
(ID1), matrix metalloproteinase 13 (MMP13), plasmino-
gen activator inhibitor 1 (PAI1, a readout for activated
Smad2/3 signaling [27–29]), (sex determining region Y)-
box 9 (SOX9), and tissue inhibitor of metalloproteinase 1
(TIMP1), as well as the reference genes glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), ribosomal protein
S19 (RPS19), hypoxanthine-guanine phosphoribosyltrans-
ferase (HPRT), and succinate dehydrogenase subunit A
(SDHA) as described previously [26]. An overview of the
primer pairs is given in Additional file 2. In addition, two
microaggregates per condition per donor were collected at
days 7 and 14, and the GAG and DNA content of the
CLC microaggregates and GAG release into the culture
medium were determined as described previously [26].
To determine caveolin-1 protein silencing efficiency,
two snap-frozen microaggregates per condition per donor
were pooled, crushed, and dissolved in radioimmunopre-
cipitation assay (RIPA) buffer at days 7 and 14. Caveolin-1
protein was measured using an enzyme-linked immuno-
sorbent assay (SEA214Ca, Cloud-Clone Corp., Houston,
TX, USA). Histopathological evaluation of the microag-
gregates was performed with Safranin O/Fast Green
staining [26] and collagen types I and II immunohisto-
chemistry (Table 1). Western blot analysis was per-
formed as described previously for pSmad2 (Ser465/
467, 60 kDa, 3101; Cell Signaling Technology, Danvers,
MA, USA) and β-actin (42 kDa, pan Ab-5; Neomarkers,
Fremont, CA, USA) [30]. CD canine CLCs (n = 200,000;
mixture of the previously used CD canine donors) were
plated per well (six-well plate, 657160, CELLSTAR®;
Greiner Bio-One, Monroe, NC, USA) in expansion
medium. After 5 days, the cells were treated with 3 ml
of chondrogenic culture medium with or without CSD.
The following conditions were tested: T2, T2C10, T2C25,
T10, T10C10, and T10C25. After 24 h of treatment, pro-
tein samples were obtained and homogenized in RIPA
buffer containing 0.6 mM phenylmethylsulfonyl fluor-
ide, 17 μg/ml aprotinin, and 1 mM sodium orthovana-
date (Sigma-Aldrich). Protein concentrations were
measured using the Qubit® Protein Assay Kit (Q32851;
Invitrogen) according to the manufacturer’s instruc-
tions. The mean volume of the protein bands on the
blots was determined by volumetric (INT*mm2) band
analysis using Quantity One software (Bio-Rad Labora-
tories, Hercules, CA, USA). The mean volume of
pSmad2 was divided by the mean volume of β-actin
(pSmad2/β-actin ratio) to correct for different protein
concentrations applied to the membranes.
Statistical analysis
Statistical analysis was performed using IBM SPSS ver-
sion 22 (IBM Armonk, NY, USA) and RStudio (version
0.96; RStudio, Boston, MA, USA) software. All data were
examined for normal distribution (Shapiro-Wilk test).
Kruskal-Wallis and Mann-Whitney U tests were per-
formed on nonnormally distributed data, whereas gener-
alized linear regression models based on analysis of
variance were used for normally distributed data. A Cox
proportional hazards model was used for genes with un-
detectable expression (cycle threshold value >40). To
find correlations between the caveolin-1/TUNEL ratio
and IVD degeneration score, partial correlations (cor-
rected for donor) were determined. All of the above-
mentioned tests were followed by a Benjamini-
Hochberg false discovery rate post hoc correction for
multiple comparisons. A p value less than 0.05 was
considered significant.
Results
Effect of in vivo caveolin-1 inactivation on the murine nu-
cleus pulposus
In vivo caveolin-1 loss did not affect the morphometry
of the murine IVDs (Additional file 3). However, there
was a distinct difference in morphology between NP
cells of WT and caveolin-1-null mice. The NP of WT
mice was rich in large, vacuolated NCs, whereas the NP
of caveolin-1-null mice contained relatively few, smaller,
nonvacuolated chondrocyte- and fibroblast-like cells at
every studied age (Fig. 1a). NCs were diffusely scattered
throughout the NP of 1.5-month-old WT mice, whereas
they were located mainly in the center of the NP, sur-
rounded by a rim of chondroid matrix in 3- and 6-
month-old WT mice. The NP cell numbers in WT mice
did not change considerably during aging, whereas NP
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Fig. 1 Effect of in vivo caveolin-1 inactivation on morphology and apoptosis of murine nucleus pulposus cells. a Hematoxylin and eosin–stained
nucleus pulposus (NP) sections of wild-type (WT) and caveolin-1 (Cav-1)-null mice at 1.5, 3, and 6 months of age. Typical large, vacuolated notochordal
cells (NCs) are present in the NP of WT mice, whereas smaller, nonvacuolated chondrocyte-like cells (CLCs) are present in the NP of caveolin-1-null
mice. b The intervertebral disc (IVD) of a 1.5-month-old WT mouse stained with a terminal deoxynucleotidyl transferase deoxyuridine triphosphate
nick-end labeling (TUNEL) assay shows only some brown apoptotic cell nuclei, whereas the IVD of a 1.5-month-old caveolin-1-null mouse shows many
positive nuclei. NP cell numbers are significantly lower in caveolin-1-null mice than in WT mice at 1.5 and 6 months of age. The proportion of apoptotic
cell nuclei (TUNEL ratio) is significantly higher in the NP of caveolin-1-null mice than in the NP of WT mice at every tested age. *p < 0.05, **p < 0.01,
***p < 0.001. n = 4–9 per age group and condition (WT or caveolin-1-null mice)
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cell numbers of caveolin-1-null mice decreased over
time with significantly fewer cells at 1.5 and 6 months of
age (p < 0.05) (Fig. 1b). At the ages tested, the proportion
of positively stained TUNEL cell nuclei (TUNEL ratio)
was significantly higher in the NP of caveolin-1-null
mice than in WT mice (p < 0.05) (Fig. 1b), indicating
that the in vivo loss of caveolin-1 induced apoptosis of
murine NP cells, leading to lower cell numbers. In vivo
caveolin-1 loss did not affect the expression of the cell
proliferation–associated protein Ki-67; there was no
positive Ki-67 staining in WT or caveolin-1-null mice
NPs (data not shown). In the caveolin-1-null mice,
GAGs and collagen type II were abundantly present in
the extracellular matrix (ECM), whereas they were
present to a lesser extent in WT NPs (Fig. 2).
Immunofluorescent staining confirmed that caveolin-
1-null NP cells expressed no caveolin-1 at the protein
level, whereas NCs of WT mice abundantly expressed
caveolin-1 in their cytoplasm and cell membranes at
every studied age (Fig. 3). In vivo caveolin-1 inactivation
increased the expression of NPPC markers Tie2 (differ-
entiation marker for dormant NPPCs [31]) and GD2
(NPPC proliferation marker [31]). Caveolin-1-null NP
cells abundantly expressed these markers at every stud-
ied age, whereas WT NCs expressed Tie2 only at
1.5 months of age and GD2 at 1.5 and 6 months of age
(Fig. 3). GD2 was intracellularly compartmentalized in
caveolin-1-null NP cells but localized in the cell mem-
brane of WT mice NCs. Moreover, the percentage of
cells expressing nuclear pSmad2 protein was signifi-
cantly higher in the 1.5-month-old murine caveolin-1-
null NPs compared with murine WT NPs of the same
age. The percentage of cells expressing pSmad2 was
significantly increased in the 3-month-old WT NPs
compared with the 1.5-month-old WT NPs. At 3 and
6 months of age, WT and caveolin-1-null NP cells
showed a similar percentage of pSmad2-positive stained
nuclei, indicating comparable levels of activated TGF-β/
Smad2 signaling (p < 0.05) (Fig. 4).
Caveolin-1 expression and apoptosis during canine IVD
degeneration
Apoptotic (TUNEL-positive) cell nuclei were observed
in healthy NC-containing NPs and in degenerated CLC-
Fig. 2 Effect of in vivo caveolin-1 (Cav-1) inactivation on extracellular
matrix production of the murine nucleus pulposus (NP). Picrosirius
red/Alcian Blue staining (a) and immunohistochemistry for collagen
type II (b) on the NP of wild-type (WT) and Cav-1-null mice. GAGs
and collagen type II are abundantly present in the extracellular
matrix of Cav-1-null mice NPs, whereas they were present to a
lesser extent in WT mice NPs. Bars indicate 100 μm. n = 4–9 per age
group and condition (WT or Cav-1-null mice)
Fig. 3 Disialoganglioside 2 (GD2) and Tie2 expression is increased in
caveolin-1 (Cav-1)-null mice. Immunofluorescent staining for Cav-1
(red), GD2 (green), and Tie2 (red) on the nucleus pulposus of wild-
type (WT) and Cav-1-null mice. The cell nuclei were stained with
4′,6-diamidino-2-phenylindole (blue). Bars indicate 25 μm. n = 2–5
per age group and condition (WT or Cav-1-null mice)
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containing NPs (Fig. 5a). NPs obtained from IVDs with
Thompson grades IV and V demonstrated significantly
more apoptotic cells than healthy and early degenerated
NPs (Thompson grades I and II) in CD and NCD dogs
(p < 0.05) (Fig. 5b). Also, there was a significant positive
correlation between apoptosis levels and IVD degener-
ation grade in CD and NCD dogs (r = 0.607 and r = 0.486,
respectively; p < 0.05) (Fig. 5b). There were no statistically
significant differences between CD and NCD dogs for
apoptosis levels per Thompson grade.
Caveolin-1 expression was localized in the cytoplasm
and cell membranes of NCs from healthy NPs and in
CLCs from (severely) degenerated NPs (Fig. 5a). No cor-
relation between caveolin-1 expression and donor age
was observed (data not shown). Also, there were no sta-
tistically significant differences between CD and NCD
dogs for caveolin-1 expression per Thompson grade.
The expression of caveolin-1 significantly increased dur-
ing IVD degeneration in CD dogs (p < 0.05) (Fig. 5c).
Caveolin-1 expression and IVD degeneration grade
(Thompson grades I–V) did not correlate in NCD dogs
(r = −0.247), while in CD dogs there was a strong posi-
tive correlation between caveolin-1 expression and IVD
degeneration grade (r = 0.719, p < 0.01) (Fig. 5c). How-
ever, given that NC-rich Thompson grade I IVDs were
available only from NCD dogs, when excluding those
Thompson grade I IVDs, caveolin-1 expression weakly
correlated with IVD degeneration for the range of
Thompson grades II–V in the NCD dogs (r = 0.349)
(Fig. 5c). No statistically significant correlation between
caveolin-1 expression and apoptosis levels was found in
CD or NCD canine NPs (data not shown).
In vitro effects of caveolin-1 on human and canine CLCs
Effect of caveolin-1 silencing in canine CLCs in vitro
With a clinical directive in mind, caveolin-1 was silenced
and CSD peptide (which mimics the function of
caveolin-1 [8, 9, 32–34]) was added to canine and hu-
man CLCs derived from degenerated IVDs to determine
whether caveolin-1 modifies TGF-β signaling in CLCs
with concurrent effects on ECM level. CAV1 messenger
RNA (mRNA) knockdown in the caveolin-1-silenced
CLCs was 70 % compared with mock-treated CLCs at
day 4 (p < 0.001) (Fig. 6a). CSD treatment upregulated
CAV1 mRNA expression in canine CLCs silenced for
caveolin-1 (p < 0.05). Caveolin-1 protein knockdown was
53 % compared with mock-treated CLCs at day 7 and
48 % at day 14 (Fig. 6a). While PAI1 expression was de-
creased in caveolin-1-silenced CLCs compared with
mock-treated CLCs (p < 0.05), ALK5 and PAI1 expression
were increased by CSD treatment of these CLCs (p < 0.01)
(Fig. 6b), which indicated activated TGF-β/Smad2/3
signaling under the influence of CSD at least at the gene
expression level. Expression of the antiapoptotic BCL2
gene was decreased by caveolin-1 silencing, whereas the
addition of CSD reversed this effect (p < 0.05) (Fig. 6b).
Gene expression of MMP13, ACAN (Fig. 6b), COL1A1,
COL2A1, SOX9, TIMP1, ALK1, ID1, CCND1, BAX, and
CASP3 (data not shown) was not significantly different be-
tween the conditions.
Fig. 4 Phosphorylated Smad2 (pSmad2) expression is lower in young wild-type (WT) than in young caveolin (Cav)-1-null mice. Immunofluorescent
staining for pSmad2 (green) on the nucleus pulposus (NP) of WT and Cav-1-null mice. The cell nuclei were stained with 4′,6-diamidino-2-phenylindole
(blue). pSmad2 protein expression (pSmad2 ratio) is significantly lower in the murine WT NP at 1.5 months of age than in the murine WT NP at
3 months of age and the murine Cav-1-null NP at 1.5 and 3 months of age. Bars indicate 25 μm. n = 2–5 per age group and condition (WT or
Cav-1-null mice). *p < 0.05
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Caveolin-1-silenced CLCs showed increased ADAMTS5
expression compared with mock-treated CLCs (p < 0.05),
whereas CSD treatment reversed this effect (p < 0.01)
(Fig. 6b). Also, the GAG content of caveolin-1-silenced
microaggregates was significantly less than in mock-
treated microaggregates at day 7 (17 %; p < 0.05), but not
at day 14 (10 %) (Fig. 6c). CSD treatment increased the
GAG content of caveolin-1-silenced microaggregates at
day 14 (14 %; p < 0.05). GAG release into the culture
medium (data not shown) and the DNA content (Fig. 6c)
of the microaggregates was not considerably different be-
tween the conditions.
All CLC microaggregates stained positive for GAGs
and collagen types I and II (Fig. 6c). In the mock-treated
microaggregates, and mainly in the caveolin-1-silenced
microaggregates supplemented with CSD, a collagen
type II–positive rim was present, but not in the
caveolin-1-silenced microaggregates not supplemented
with CSD.
Dose–response effect of caveolin-1 peptide on canine and
human CLCs in vitro
Because CSD treatment rescued the effects of caveolin-1
silencing and exerted anabolic effects on canine CLCs by
modifying TGF-β signaling at the gene expression level,
different concentrations (i.e., 2 ng/ml TGF-β1 [T2],
10 ng/ml TGF-β1 [T10], 10 μM CSD [C10], and 25 μM
CSD [C25]) were tested to determine the additive effect
of CSD on TGF-β1 treatment of human, CD, and NCD
canine CLCs. The DNA content of CD and NCD canine
T10-treated microaggregates was significantly higher
than that of T2-treated microaggregates (p < 0.05),
whereas this was not observed in human microaggregates
Fig. 5 Caveolin-1 expression and apoptosis levels are increased
during canine intervertebral disc (IVD) degeneration. a Terminal
deoxynucleotidyl transferase deoxyuridine triphosphate nick-end
(TUNEL) assay and immunohistochemical staining for caveolin-1. Part
of a healthy canine nucleus pulposus (NP) (Thompson grade I) and a
severely degenerated canine NP (Thompson grade V) with brown
apoptotic notochordal cell (NC) nuclei (TUNEL) and brown NC
membranes and cytoplasm (caveolin-1). b The mean TUNEL ratio
(the proportion of positively stained TUNEL nuclei in the NP) per
Thompson degeneration score of canine IVDs. Apoptosis levels
increased during canine IVD degeneration in chondrodystrophic (CD)
and nonchondrodystrophic (NCD) dogs. The r values indicate the
partial correlation between the mean TUNEL ratio and IVD degeneration
grade (Thompson grade range I–V) for CD and NCD dogs. *p< 0.05
(significance indicated for changes related to Thompson grade). c The
mean caveolin-1 ratio (the proportion of the total NP surface area that
stained positive for caveolin-1) per Thompson degeneration score of
canine IVDs. The r values indicate the partial correlation between the
mean caveolin-1 ratio and IVD degeneration grade (Thompson score
range II–V) for CD and NCD dogs. Caveolin-1 protein expression increases
during canine IVD degeneration in CD and NCD dogs. *p < 0.05
(significance indicated for changes related to Thompson grade).
n = 37 IVD samples from 16 dogs
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(Fig. 7). Only in NCD canine donors, T2C25-treated
microaggregates showed an increased DNA content com-
pared with T2C10-treated microaggregates (p < 0.05). CSD
treatment did not affect the DNA content of human and
CD canine microaggregates.
In CD and NCD donors, the GAG content of the
T2C25-treated microaggregates was significantly higher
(35 % for CD, 25 % for NCD) than the GAG content of
T2-treated microaggregates (Fig. 7). Additionally, only in
CD donors was the GAG content of the T10C25-treated
microaggregates significantly higher (26 %) than the
GAG content of the T10-treated microaggregates. GAG
release in the culture medium was decreased by approxi-
mately three times in T2C25-treated CLC microaggre-
gates compared with T2-treated CLC microaggregates in
all species (p < 0.05) (Fig. 7). Total GAG production
(GAG content in the microaggregates plus GAG release
into the culture medium) appeared to be 20–40 % de-
creased by 25 μM CSD treatment in all species and was
significantly decreased in T2C25-treated CD and NCD
canine CLCs compared with T2- and T2C10-treated CD
and NCD canine CLCs (p < 0.05), but not significantly
different between the differentially treated human CLCs
(data not shown). The GAG content of human CLC
microaggregates was lower than the GAG content of CD
and NCD canine microaggregates. In contrast to canine
CLC microaggregates, human CLC microaggregates dem-
onstrated no collagen type II protein deposition (Fig. 7).
Furthermore, CSD treatment increased collagen type I de-
position in human CLC microaggregates, whereas this
was not observed in canine CLC microaggregates.
Western blot analysis demonstrated that pSmad2 pro-
tein expression was 1.7 times higher in CD canine CLCs
treated with 2 ng/ml TGF-β1 than in those treated with
10 ng/ml TGF-β1 (Fig. 8). pSmad2 protein expression
was 1.3–1.5 times higher in the canine CLCs treated
Fig. 6 The effect of in vitro caveolin (Cav)-1 silencing on
chondrocyte-like cells (CLCs) from chondrodystrophic dogs. In vitro
Cav-1 silencing decreased transforming growth factor-β/Smad2/3
signaling and canine CLC extracellular matrix deposition, while
10 μM Cav-1 scaffolding domain peptide (CSD) supplementation
rescued this effect. a Cav-1 messenger RNA (n-fold change ± SD)
and protein knockdown by microaggregates silenced for Cav-1
(siRNA). The Cav-1 protein level in the mock-treated microaggregates at
day 7 was set at 100 %. b Real-time quantitative polymerase chain
reaction results (n-fold change ± SD). Gene expression in the nontreated
CLC microaggregates was set at 1. c DNA and glycosaminoglycan (GAG)
content (corrected for DNA content) of the canine CLC microaggregates
with corresponding Safranin O/Fast Green, collagen type I, alpha 1 (Col I),
and collagen type II, alpha 1 (Col II) immunohistochemically stained
sections. Bars indicate 100 μm. n = 6. ACAN aggrecan, BCL2 B-cell
CLL/lymphoma 2, ALK5 activin receptor-like kinase 5, PAI1
plasminogen activator inhibitor 1, ADAMTS5 a disintegrin and
metalloproteinase with thrombospondin motifs 5, MMP13 matrix
metalloproteinase 13. *p < 0.05, **p < 0.01
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with 10 or 25 μM CSD and 2 ng/ml TGF-β1 than in
those treated with only 2 ng/ml TGF-β1 (Fig. 8). Further-
more, pSmad2 protein expression was 1.1–1.2 times
higher in the CLCs treated with 10 or 25 μM CSD and
10 ng/ml TGF-β1 than in those treated with only
10 ng/ml TGF-β1 (Fig. 8). Altogether, this indicates
that CSD peptide treatment enhanced TGF-β/pSmad2
signaling.
Discussion
The present study demonstrates that caveolin-1 plays a
role in IVD degeneration. In vivo studies with murine
caveolin-1-null NPs demonstrated that caveolin-1 was
essential for NC preservation. Furthermore, we have
demonstrated that caveolin-1 expression and apoptosis
levels were significantly increased during CD canine
IVD degeneration. In addition, in vitro caveolin-1 silen-
cing decreased CLC ECM deposition, while CSD supple-
mentation increased TGF-β/pSmad2 signaling at the
gene and protein expression levels and enhanced the
anabolic effects of TGF-β1 on CLCs, resulting in higher
ECM deposition. Taken together, this may indicate that
the increased caveolin-1 expression during IVD degener-
ation facilitates an anabolic reparative response of the
CLCs at least by modifying TGF-β signaling rather than
being merely correlated with CLC apoptosis.
Caveolin-1 is essential for NC physiology
Histological analysis of caveolin-1-null NPs revealed that
apoptotic cells were present in the healthy WT murine
NP at 1.5, 3, and 6 months of age, implying that during
IVD tissue homeostasis, there is physiologic turnover of
NP cells (they proliferate and undergo apoptosis).
Affirmatively, previous work already demonstrated apop-
totic cells in IVDs from 2-week-old WT mice [35].
Caveolin-1-null NPs showed the absence of typical NCs
in favor of chondrocyte/fibroblast-like cells with an in-
creased apoptotic activity, suggesting that caveolin-1 is
essential for NC preservation. In line with this thought,
NPs of NCD dogs with Thompson grade I, rich in NC
cells, abundantly expressed caveolin-1, while the
caveolin-1-null mice had lost their NCs already when
they were skeletally mature (young adult), which is ra-
ther comparable with the loss of NCs in young adult CD
Fig. 7 The dose–response effect of caveolin-1 on canine and human chondrocyte-like cells (CLCs) in vitro. DNA content, glycosaminoglycan (GAG)
content (corrected for DNA content), and GAG release into the culture medium of human and chondrodystrophic (CD) and nonchondrodystrophic
(NCD) canine CLC microaggregates with corresponding Safranin O (Saf O)/Fast Green collagen types I (Col I) and II (Col II) immunohistochemically
stained sections. Generally, the GAG content was increased in the microaggregates treated with 25 μM caveolin-1 scaffolding domain (CSD), whereas
the GAG release in the culture medium was decreased in these 25 μM CSD-treated microaggregates. T2 2 ng/ml transforming growth factor (TGF)-β1,
T10 10 ng/ml TGF-β1, C10 10 μM CSD, C25 25 μM CSD. Bars indicate 100 μm. n = 5 (CD and NCD) and n = 3 (human). Two microaggregates were
analyzed per donor and condition. *p < 0.05
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dogs and humans. In the NP of 1.5-month-old caveolin-
1-null mice (with lower total NP cells numbers than WT
mice), Tie2+/GD2+ progenitor cells were present, and
TGF-β signaling mediated by pSmad2 probably facili-
tated abundant ECM deposition. Affirmatively, Tie2
+/GD2+ NP cells have been shown to possess superior
ECM production, self-renewal, multipotent differenti-
ation, and proliferation capacity [31]. Increased cell pro-
liferation is associated with late-stage IVD degeneration
[36]. Notably, the NPPC proliferation marker GD2 was
expressed in caveolin-1-null and WT mice NPs, but Ki-
67 positivity was not detected. The short Ki-67 protein
half-life (90 minutes) and nutritionally deprived NP en-
vironment may explain the absence of Ki-67 in murine
NPs [36]. GD2 appeared intracellularly compartmental-
ized in caveolin-1-null NP cells but localized to the cell
membrane of WT NCs. We hypothesize that in the
caveolin-1-null NP phenotype, GD2 may not mark pro-
liferating cells per se if the different localization could
render GD2 inactive, but researchers in future studies
should look into the functionality of GD2 in caveolin-1-
null NP cells.
Altogether, caveolin-1 plays a role in the preservation
of healthy NCs because in vivo inactivation of caveolin-1
induced a change in cell phenotype from NCs toward
CLCs with high apoptotic activity in mice. Activated
NPPCs and TGF-β/pSmad2 signaling probably resulted
into GAG- and collagen-rich ECM deposition in the
caveolin-1-null mice NP. The caveolin-1-null mice
showed several metabolic/endocrine disorders [37–39]
that could have influenced their NP phenotype (e.g., insu-
lin resistance leading to diabetes mellitus, which has been
associated with premature NC senescence and apoptosis)
[40]. Further studies need to be concentrated at earlier
stages of development to delineate how caveolin-1 pre-
serves NCs, including modification of mitogen-activated
protein kinase/extracellular signal-regulated kinase, Wnt
[15], Indian hedgehog and/or sonic hedgehog signaling
pathways [41, 42], and/or glucose transport [43, 44].
Caveolin-1 increases during IVD degeneration, mediating
a reparative response
Caveolin-1 is known to induce apoptosis via—among
others—cell cycle arrest in the G2/M phase [45] and by
influencing the expression of the antiapoptosis protein
survivin [46, 47]. Caveolin-1 may induce senescence in
CLCs, given that, in NPs derived from degenerated CD
canine and human IVDs, caveolin-1 expression [16] and
apoptosis levels were positively correlated with IVD de-
generation grade. However, a causative relationship in
the IVD remains to be determined. On the basis of the
results of the present study, it is tempting to hypothesize
that the increased caveolin-1 expression in degenerated
IVDs may be part of an ultimate attempt at (unsuccess-
ful) repair. With a clinical directive in mind (degenerated
human and canine IVDs contain almost 100 % CLCs),
the effect of caveolin-1 was investigated in human and
canine CLCs derived from degenerated IVDs by silen-
cing for caveolin-1 and/or supplementing with CSD pep-
tide. Caveolin-1 silencing decreased antiapoptotic BCL2
expression, whereas CSD addition increased it to base-
line levels again, opposing the hypothesis that caveolin-1
itself induces CLC apoptosis. Furthermore, caveolin-1 si-
lencing increased ADAMTS5 expression and decreased
the GAG content of the microaggregates, whereas when
the canine CLCs were treated with CSD, ADAMTS5 ex-
pression decreased and the GAG content was restored.
In line with this, GAG release was decreased in 25 μM
CSD-treated human and canine CLCs. Notably, caveolin-1
silencing and CSD supplementation did not influence
collagen type I deposition by canine CLCs, while its de-
position was increased by CSD treatment in human
CLCs. It is plausible that caveolin-1 exerts a protective
effect by decreasing ECM degradation, given its well-
described anti-inflammatory properties [48–50]. This
altogether implies that decreased GAG degradation re-
sulted in the significantly increased GAG content of
CSD-treated canine CLCs. The underlying mechanisms
for the latter could be decreased ECM degradation and/
or more collagen type II protein expression that enables
the deposition [51] and prevents the release of GAGs.
Fig. 8 Caveolin-1 enhances transforming growth factor
(TGF)-β/phosphorylated Smad2 (pSmad2) signaling in canine
chondrocyte-like cells (CLCs) in vitro. Western blot analysis for pSmad2
and β-actin protein expression in chondrodystrophic (CD) canine CLCs
after 24 h of treatment, expressed as pSmad2/β-actin ratio. T2 2 ng/ml
TGF-β1, T10 10 ng/ml TGF-β1, C10 10 μM CSD, C25 25 μM CSD. The
pSmad2/β-actin ratio in the T2-treated CLCs was set at 1
Bach et al. Arthritis Research & Therapy  (2016) 18:59 Page 12 of 15
The results of this study imply that caveolin-1 regu-
lates TGF-β signaling in CLCs in vitro, because caveolin-
1 silencing decreased, whereas CSD supplementation in-
creased TGF-β/Smad2 signaling at the gene and protein
expression levels. TGF-β signals through two membrane
TGF-β receptors type I (ALK1 and ALK5) and one TGF-
β receptor type II. These TGF-β receptors have been
demonstrated to colocalize with caveolin-1 [20]. TGF-β
receptor type II phosphorylates TGF-β receptor type I.
When ALK5 is phosphorylated, Smad2/3 signaling be-
comes activated and ECM is produced. However, when
ALK1 is phosphorylated, Smad1/5/8 signaling becomes
activated, which inhibits Smad2/3 signaling and ECM
production [52, 53]. In this study, we have demonstrated
that CSD enhanced the anabolic effect of TGF-β1 in
terms of ECM deposition in the microaggregates.
Caveolin-1 silencing decreased PAI1 (a classical readout
for activated Smad2/3 TGF-β signaling [27–29]) gene
expression, while CSD supplementation increased ALK5
and PAI1 gene expression, did not influence ALK1 or ID1
(readout for activated Smad1/5/8 signaling) gene expres-
sion, and increased pSmad2 protein expression. This all
indicates that caveolin-1 indeed enhanced TGF-β/Smad2/
3 signaling.
There is evidence that caveolin-1 acts differently ac-
cording to stimulating and/or inhibiting signals and cel-
lular context (e.g., cell type, age, and disease and/or
health stage of the tissue) [7, 11, 54]. In the present
study, caveolin-1 enhanced TGF-β signaling mediated by
pSmad2 in CLCs from degenerated IVDs in vitro, while
the opposite was true in earlier reports [14, 55–57]. In
line with our results, however, TGF-β signaling is re-
duced in caveolin-1-deficient fibroblasts [58] and regen-
erating hepatocytes of caveolin-1-null mice [20].
Notably, in caveolin-1-silenced canine CLCs, ECM pro-
duction was decreased, whereas in caveolin-1-null mice,
which initially contained primarily NCs, abundant ECM
was deposited. This implies that caveolin-1 may indeed
have different functions in NCs and CLCs, because
caveolin-1 is required for NC preservation, whereas in
CLCs it may be related to apoptosis and/or it may influ-
ence signaling pathways (such as TGF-β) that support
ECM deposition.
Conclusions
The present study demonstrates that caveolin-1 plays a
role in IVD degeneration. The abundant expression of
caveolin-1 in NCs from NCD dogs and the loss of
healthy NCs in the NP of caveolin-1-null mice indicate
that caveolin-1 supports preservation of the NC pheno-
type. In the CD canine NP, both caveolin-1 expression
and apoptosis levels had a positive correlation with IVD
degeneration grade, indicating that caveolin-1 may be re-
lated with CLC apoptosis. Nevertheless, ECM deposition
was decreased by in vitro caveolin-1 silencing of canine
CLCs, whereas CSD peptide increased TGF-β/pSmad2
signaling at the gene and protein expression levels and
enhanced the anabolic effects of TGF-β1 with concomi-
tant increased ECM deposition. This implies that the in-
creased caveolin-1 expression during IVD degeneration
may be an anabolic repair response rather than merely
being correlated with CLC apoptosis. Further studies are
needed to investigate how caveolin-1 modifies other sig-
naling pathways and facilitates IVD repair.
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